Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amgen 1Q Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Amgen 1Q Results

Horizon Therapeutics acquisition adds $914 million of sales in the quarter.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen
1Q Revenues: $7.4 billion (+22%)
1Q Loss: $113 million (earnings were $2.8 billion 1Q23)
Comments: Repatha (evolocumab) sales increased 33% to $517 million in the quarter, driven by 44% volume growth. TEZSPIRE (tezepelumab-ekko) generated $173 million of sales in the quarter, up 80%, primarily driven by volume growth. Otezla (apremilast) sales were $394 million, an increase of 1%.  Enbrel (etanercept) generated $567 million of sales, down 2%. AMJEVITA/AMGEVITA (adalimumab) generated $168 million of sales, up 2%. EVENITY (romosozumab-aqqg) sales increased 35% to $342 million, primarily driven by volume growth. BLINCYTO (blinatumomab) sales increased 26% to $244 million. TAVNEOS (avacopan) sales were $51 million, up 122% driven by volume growth. Prolia (denosumab) generated $999 million of sales, up 8% driven by volume growth Vectibix (panitumumab) sales were $247 million, up 6%. KYPROLIS (carfilzomib) sales increased 5% to $376 million. XGEVA (denosumab) sales increased 5% to $561 million. Nplate (romiplostim) generated $317 million of sales in the quarter, down 12%. MVASI (bevacizumab-awwb) sales were flat at $202 million.
 
Results include $914 million of sales from the Horizon Therapeutics acquisition, driven by TEPEZZA (teprotumumab-trbw), KRYSTEXXA (pegloticase) and UPLIZNA (inebilizumab-cdon). TEPEZZA (teprotumumab-trbw) generated $424 million of sales in the quarter. TEPEZZA is the first and only FDA-approved treatment for thyroid eye disease (TED). KRYSTEXXA (pegloticase) generated $235 million of sales. KRYSTEXXA is the first and only FDA-approved treatment for chronic refractory gout. UPLIZNA (inebilizumab-cdon) sales were $80 million in the quarter. UPLIZNA is used to treat adults with neuromyelitis optica spectrum disorders.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters